Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused ...

Right now, patients with obesity and cirrhosis have few treatments for their progressive liver disease, but a new study ...

Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast growth factor 21 analog, designed to treat patients with biopsy-confirmed ...

Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

CHICAGO, NY, UNITED STATES, January 21, 2025 /EINPresswire / -- The global liver fibrosis treatment market is set to witness significant expansion over the coming decade, with revenues anticipated ...

After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

Akero Therapeutics, Inc. (NASDAQ:AKRO) released preliminary topline week 96 results from SYMMETRY Phase 2b study evaluating ...

Beta-blockers have been a standard treatment for managing portal hypertension for many years. However, they are effective in ...

Most ICBs in England do not have effective referral pathways for diagnosing and managing liver disease, an analysis has shown ...

(ETNB) stock jumped 40% Monday, stoked by positive data for Akero's (AKRO) drug efruxifermin in the treatment of compensated ...